Sildenafil exposure describes the magnitude and time course of parent-drug concentrations in systemic circulation. It is broader than any one pharmacokinetic metric: AUC summarizes integrated exposure, Cmax describes peak concentration and the complete concentration-time curve shows how those measurements develop and decline.
Current sildenafil labeling provides a useful quantitative framework. Mean absolute oral bioavailability is approximately 41%, pharmacokinetics are dose-proportional over the recommended dose range and exposure can change substantially when clearance is altered by age, organ impairment or metabolic drug interactions.
This page connects those findings rather than duplicating each individual PK topic. The AUC page focuses on integrated exposure and its calculation, while the Cmax page focuses on peak concentration.
In pharmacokinetics, systemic exposure describes the concentrations of sildenafil that occur in circulation and how those concentrations change over time after administration. The concept therefore includes both the magnitude and shape of the plasma concentration-time profile.
AUC and Cmax are the two most commonly discussed quantitative exposure measures, but they answer different questions. AUC integrates concentration across time, whereas Cmax identifies the highest observed concentration within the sampled profile.
Exposure is the output of the complete PK system. Dose and bioavailability determine systemic input, while distribution, metabolism and clearance shape what happens after sildenafil reaches circulation.
| Concept | What It Describes |
|---|---|
| Systemic exposure | Overall magnitude and time course of circulating sildenafil. |
| AUC | Integrated concentration-time exposure. |
| Cmax | Highest observed plasma concentration. |
| Tmax | Time at which the observed Cmax occurs. |
| Concentration-time profile | Complete pattern from systemic appearance through decline. |
The concentration-time curve provides the visual framework from which sildenafil exposure metrics are interpreted. Concentration rises rapidly after oral absorption, reaches Cmax at Tmax and then declines as distribution and elimination exceed continuing systemic input.
Current labeling reports fasted peak concentrations within approximately 30 to 120 minutes, with a median Tmax of about 60 minutes. Parent sildenafil and its major active metabolite then decline with terminal half-lives of approximately 4 hours.
AUC is the area integrated beneath this profile, while Cmax is only its maximum point. The complete interpretation of the curve itself remains on the sildenafil concentration-time page.
| Curve Feature | Exposure Interpretation |
|---|---|
| Early rise | Reflects systemic appearance after absorption. |
| Cmax | Peak exposure magnitude. |
| Tmax | Peak exposure timing; median about 60 minutes fasted. |
| AUC | Integrated exposure across the profile. |
| Late decline | Reflects distribution and elimination, with terminal half-life about 4 hours. |
AUC is often used as shorthand for total systemic exposure because it integrates sildenafil concentration across a defined time interval. It is one of the most informative quantitative measures of how much circulating parent-drug exposure occurred.
Exposure is nevertheless broader than AUC. Two profiles can produce similar integrated areas while having different Cmax values, Tmax values or concentration persistence, so the same AUC does not imply an identical concentration-time shape.
AUC is also influenced by both systemic input and clearance. After oral administration, interpreting a change in AUC requires considering dose and bioavailability rather than assuming that every increase represents reduced clearance. The detailed metric remains on the sildenafil AUC page.
| Question | Relevant Concept |
|---|---|
| How much integrated systemic exposure occurred? | AUC |
| How high did concentration peak? | Cmax |
| When did the peak occur? | Tmax |
| What was the complete concentration pattern? | Exposure profile |
Cmax describes the maximum observed sildenafil concentration and therefore captures peak exposure rather than total exposure. It is particularly sensitive to the rate at which sildenafil enters systemic circulation.
A change in Cmax does not have to match the change in AUC. For example, in mild-to-moderate hepatic impairment, current labeling reports sildenafil Cmax approximately 47% higher while AUC increased approximately 85%. The same condition therefore altered peak and integrated exposure by different amounts.
This distinction is central to exposure interpretation: one concentration point cannot represent the entire PK profile. Peak-specific analysis remains on the sildenafil Cmax page.
| Metric | Primary Exposure Meaning | Hepatic-Impairment Example |
|---|---|---|
| Cmax | Peak concentration | Approximately +47% |
| AUC | Integrated systemic exposure | Approximately +85% |
| Interpretation | Different dimensions of the same exposure profile | Do not assume equal percentage changes |
Administered dose is a primary determinant of sildenafil exposure because it establishes the amount of drug available for systemic input. Current U.S. labeling states that sildenafil pharmacokinetics are dose-proportional over the recommended dose range.
Dose proportionality means that AUC and peak exposure generally increase predictably as dose increases under comparable conditions. It does not mean clinical effect or adverse-event probability must increase by the same percentage.
Dose also cannot explain every difference in measured concentration because bioavailability and clearance can change exposure independently. The research relationship between administered amount and PK measurements is covered on the sildenafil dose proportionality page.
| Dose-Exposure Concept | Sildenafil Context |
|---|---|
| Higher dose | Generally produces greater systemic exposure under comparable conditions. |
| Recommended dose range | Sildenafil PK is described as dose-proportional. |
| Same dose, different clearance | Exposure can differ substantially. |
| Same dose, different bioavailability | Systemic input and exposure can differ. |
Absorption determines how rapidly orally administered sildenafil becomes available for systemic circulation. The rate of absorption is especially visible in the rising portion of the concentration-time profile and in Tmax and Cmax.
A faster rate of systemic input can produce an earlier and higher peak under otherwise comparable conditions, while slower absorption can shift the peak later and reduce its height. Those changes do not necessarily produce the same proportional change in integrated AUC.
This separation between rate and extent is why an exposure framework needs more than Cmax alone. The mechanisms that occur before systemic appearance are explained in detail on the sildenafil absorption page.
| Absorption Feature | Most Visible Exposure Effect |
|---|---|
| Faster systemic appearance | Earlier concentration rise and potentially higher Cmax. |
| Slower systemic appearance | Later Tmax and potentially lower Cmax. |
| Extent of systemic input | Contributes to AUC. |
| Absorption alone | Does not determine clearance or later concentration decline. |
Absolute bioavailability describes the fraction of an oral sildenafil dose that reaches systemic circulation as unchanged parent drug. Current labeling reports mean absolute oral bioavailability of approximately 41%, with a reported range of 25% to 63%.
The 41% value should not be interpreted as meaning that only 41% of sildenafil is absorbed from the gastrointestinal tract. Bioavailability reflects the net result of absorption plus presystemic losses before unchanged parent drug reaches systemic circulation.
For a given oral dose, systemic availability directly contributes to AUC together with clearance. Bioavailability therefore helps explain why administered dose and measured exposure are related but not identical concepts. The fraction-reaching-circulation framework remains on the sildenafil bioavailability page.
| Bioavailability Concept | Sildenafil Context |
|---|---|
| Mean absolute oral bioavailability | Approximately 41%. |
| Reported range | Approximately 25% to 63%. |
| What it represents | Fraction of oral dose reaching systemic circulation unchanged. |
| What it is not | A direct measure of clinical effect or simply the fraction absorbed from the intestine. |
Sildenafil is cleared predominantly through hepatic metabolism, principally by CYP3A4 with CYP2C9 providing a minor route. Changes in those pathways can substantially change parent-drug systemic exposure.
CYP inhibition demonstrates the relationship quantitatively. Erythromycin increased sildenafil Cmax by approximately 160% and AUC by approximately 182%, while saquinavir increased Cmax by approximately 140% and AUC by approximately 210% in labeled interaction studies.
Ritonavir produced the most extreme labeled example, increasing sildenafil Cmax approximately fourfold and AUC approximately elevenfold. These data show how metabolism can reshape the entire exposure profile rather than simply producing a small concentration change. The enzyme pathways themselves remain on the sildenafil metabolism page.
| Metabolic Context | Cmax Change | AUC Change |
|---|---|---|
| Erythromycin | Approximately +160% | Approximately +182% |
| Saquinavir | Approximately +140% | Approximately +210% |
| Ritonavir | Approximately 4-fold | Approximately 11-fold |
Clearance links drug removal with systemic exposure. If oral input is otherwise comparable, lower clearance allows sildenafil concentrations to remain greater for longer and therefore increases AUC.
This relationship is visible in several labeled special-population studies. Severe renal impairment reduced sildenafil clearance and approximately doubled both AUC and Cmax; mild-to-moderate hepatic impairment reduced clearance and increased AUC by approximately 85% and Cmax by approximately 47%.
These examples also demonstrate that clearance changes can affect multiple parts of the profile differently. The quantitative removal parameter and the distinction between systemic clearance and CL/F are covered on the sildenafil clearance page.
| Clearance Context | Observed Exposure Effect |
|---|---|
| Lower clearance | Generally increases AUC when systemic input is comparable. |
| Severe renal impairment | AUC and Cmax approximately doubled. |
| Child-Pugh A/B hepatic impairment | AUC approximately +85%; Cmax approximately +47%. |
| Higher metabolic clearance | Can reduce systemic exposure. |
Food provides a useful example of why exposure should not be reduced to one number. When conventional sildenafil tablets are administered with a high-fat meal, current labeling reports a mean Tmax delay of approximately 60 minutes and a mean Cmax reduction of approximately 29%.
The major labeled effect is therefore visible in the shape and timing of the early concentration profile: sildenafil reaches its maximum concentration later and at a lower peak. A 29% lower Cmax should not automatically be translated into a 29% reduction in AUC, clinical effect or duration.
This example illustrates why Cmax, Tmax and integrated exposure need separate interpretation. Detailed meal-effect evidence remains on the sildenafil food-effects page.
| Food-Effect Parameter | Labeling Observation | Exposure Interpretation |
|---|---|---|
| Tmax | Mean delay approximately 60 minutes | Peak occurs later. |
| Cmax | Mean reduction approximately 29% | Peak concentration is lower. |
| AUC | Not represented by the Cmax percentage | Integrated exposure requires separate assessment. |
Sildenafil exposure varies because several determinants differ between populations and individuals. Current labeling provides direct examples involving age, renal function, hepatic function and metabolic drug interactions.
Healthy volunteers aged 65 years or older had approximately 84% higher total sildenafil AUC than healthy volunteers aged 18 to 45 years because clearance was reduced. Importantly, the increase in free unbound sildenafil AUC was smaller, approximately 45%, because age-related differences in plasma protein binding affected total and unbound exposure differently.
Severe renal impairment approximately doubled parent sildenafil AUC and Cmax, while mild-to-moderate hepatic impairment increased AUC by approximately 85% and Cmax by approximately 47%. These findings show why exposure variability is best interpreted through measured PK parameters rather than generic statements that people metabolize drugs differently. Broader sources of variability remain on the sildenafil PK variability page.
| Variation Context | Sildenafil Exposure Finding |
|---|---|
| Age ≥65 years | Total parent sildenafil AUC approximately +84%. |
| Age ≥65 years, unbound sildenafil | Free AUC approximately +45%. |
| Severe renal impairment | Parent AUC and Cmax approximately doubled. |
| Child-Pugh A/B hepatic impairment | AUC approximately +85%; Cmax approximately +47%. |
| Strong metabolic inhibition | Can produce several-fold increases in systemic exposure. |
Terminal half-life describes the time scale of late concentration decline rather than the total amount of sildenafil exposure. Current labeling reports terminal half-lives of approximately 4 hours for both parent sildenafil and its major circulating active metabolite.
Half-life influences how long concentrations persist, but AUC also depends on the level of systemic input and clearance. Two profiles can therefore share a similar terminal half-life while differing markedly in Cmax or AUC.
The ritonavir interaction illustrates this distinction dramatically: sildenafil exposure increased approximately elevenfold and late plasma concentrations remained much higher, demonstrating that a complete exposure profile cannot be summarized by quoting the usual 4-hour half-life alone. The time-based elimination concept remains on the sildenafil half-life page.
| Parameter | Exposure Role |
|---|---|
| Terminal half-life | Describes the time scale of late concentration decline. |
| Typical sildenafil value | Approximately 4 hours. |
| Cmax | Describes maximum observed concentration. |
| AUC | Describes integrated systemic exposure. |
| Interaction-driven exposure change | Can substantially alter the profile even when half-life alone is not the primary summary metric. |
Systemic exposure is a pharmacokinetic measurement framework, not a direct measure of erectile response, therapeutic benefit or adverse-effect severity. A percentage increase in AUC or Cmax cannot be converted into the same percentage increase in clinical effect.
This distinction matters when interpreting the large exposure changes seen with organ impairment or CYP inhibition. An elevenfold AUC increase is a pharmacokinetic observation; it does not mean an elevenfold increase in efficacy, duration or any single physiological response.
Clinical response emerges from the relationship between active concentrations, PDE5 inhibition, physiological signaling and individual pharmacodynamic sensitivity. The concentration-effect relationship is covered on the sildenafil pharmacodynamics page.
| Domain | Question |
|---|---|
| Pharmacokinetics | What sildenafil concentrations occur and how do they change over time? |
| Systemic exposure | What peak and integrated circulating exposure occurs? |
| Pharmacodynamics | How does that exposure translate into biological activity? |
| Clinical response | What outcome is observed in a particular clinical context? |
Sildenafil exposure is best understood as the integrated result of systemic input and removal. Oral dose and bioavailability determine how much unchanged parent drug reaches circulation, while absorption rate shapes the early peak and metabolism plus clearance determine how the profile declines.
The quantitative examples fit that framework together: mean oral bioavailability is approximately 41%; a high-fat meal produces a later, lower peak; age ≥65 years increases total AUC by approximately 84%; severe renal impairment approximately doubles AUC and Cmax; hepatic impairment raises AUC more than Cmax; and strong metabolic inhibition can increase exposure several-fold.
AUC, Cmax and Tmax therefore should be read as complementary views of one changing concentration-time system rather than competing definitions of exposure. For the complete ADME framework, the sildenafil pharmacokinetics hub connects exposure with absorption, distribution, metabolism, clearance and half-life.
| Exposure Question | Sildenafil-Specific Framework |
|---|---|
| How much oral dose reaches systemic circulation unchanged? | Mean absolute bioavailability approximately 41%. |
| How is total systemic exposure summarized? | AUC. |
| How is peak exposure summarized? | Cmax. |
| What can alter early peak shape? | Absorption conditions such as a high-fat meal. |
| What can substantially increase exposure? | Reduced clearance, organ impairment or CYP inhibition. |
| Does more exposure equal proportionally more clinical effect? | No. |
Sildenafil exposure describes the magnitude and time course of circulating parent-drug concentrations after administration. AUC measures integrated exposure, while Cmax measures peak concentration.
Reduced clearance associated with older age, severe renal impairment or hepatic impairment can increase exposure, and CYP3A4 inhibitors can produce even larger changes. For example, ritonavir increased sildenafil AUC approximately elevenfold in a labeled interaction study.
A high-fat meal changes the early exposure profile by delaying mean Tmax by about 60 minutes and reducing mean Cmax by about 29%. Those changes should not be interpreted as an identical percentage change in total AUC or clinical effect.
In current labeling, severe renal impairment approximately doubled sildenafil AUC and Cmax. Mild-to-moderate hepatic impairment increased AUC by approximately 85% and Cmax by approximately 47%.
Yes. Healthy volunteers aged 65 years or older had approximately 84% higher total sildenafil AUC than younger adults in labeling data. The increase in free unbound sildenafil AUC was smaller, approximately 45%, because protein-binding differences also affected the comparison.
No. AUC and Cmax are pharmacokinetic measures. Clinical response depends on pharmacodynamic relationships and cannot be calculated as the same percentage or fold-change as systemic exposure.